Sanofi (NASDAQ:SNY) Cut to Hold at StockNews.com

StockNews.com cut shares of Sanofi (NASDAQ:SNY) from a buy rating to a hold rating in a report released on Friday morning.

Separately, Citigroup raised Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Two investment analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Stock Down 0.1 %

SNY stock opened at $48.46 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The firm has a market capitalization of $122.98 billion, a P/E ratio of 24.72, a P/E/G ratio of 1.22 and a beta of 0.58. Sanofi has a 52-week low of $45.22 and a 52-week high of $58.97. The company’s 50 day simple moving average is $51.90 and its 200-day simple moving average is $52.11.

Sanofi (NASDAQ:SNY) last announced its earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The company had revenue of $13.44 billion for the quarter, compared to the consensus estimate of $16.59 billion. During the same period in the previous year, the business earned $2.55 EPS. The company’s revenue was up 12.3% on a year-over-year basis. As a group, equities research analysts anticipate that Sanofi will post 4.28 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Stablepoint Partners LLC lifted its stake in shares of Sanofi by 0.8% in the 3rd quarter. Stablepoint Partners LLC now owns 23,893 shares of the company’s stock valued at $1,377,000 after purchasing an additional 189 shares during the last quarter. PDS Planning Inc lifted its position in shares of Sanofi by 3.1% during the 3rd quarter. PDS Planning Inc now owns 6,643 shares of the company’s stock worth $383,000 after purchasing an additional 200 shares during the last quarter. Eagle Ridge Investment Management boosted its stake in Sanofi by 3.8% during the 3rd quarter. Eagle Ridge Investment Management now owns 5,571 shares of the company’s stock valued at $321,000 after purchasing an additional 203 shares during the period. Financial Advocates Investment Management grew its holdings in Sanofi by 3.4% in the 3rd quarter. Financial Advocates Investment Management now owns 6,327 shares of the company’s stock valued at $365,000 after buying an additional 206 shares during the last quarter. Finally, Angeles Investment Advisors LLC increased its position in Sanofi by 1.9% in the 3rd quarter. Angeles Investment Advisors LLC now owns 11,323 shares of the company’s stock worth $653,000 after buying an additional 210 shares during the period. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.